Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis
Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis
复制标题
DOI：
10.1080/03009742.2018.1466362
复制
发表时间：
2019-01-02
影响因子：
2.1
通讯作者：
Pedersen-Zbinden, B.
中科院分区：
文献类型：
--
作者：
Hetland, M. L.;Ostergaard, M.;Pedersen-Zbinden, B.
目的：研究早期类风湿关节炎（RA）患者的临床和影像学状况，并确定11年随访时功能状态和糜烂进展的基线预测因素。研究方法：对丹麦制药商发起的随机对照CIMESTRA试验中招募的患者进行随访，该试验研究了甲氨蝶呤和关节内糖皮质激素联合或不联合环孢菌素的2年靶向治疗干预。在基线和11年时评估28关节疾病活动度评分（DAS 28）、健康评估问卷（HAQ）评分和总Sharp货车der Heijde评分（TSS）。对单侧手腕的基线磁共振成像（MRI）进行评分（OMERACT RAMRIS）。在96例HAQ（11岁）和TSS 0 - 11岁增量作为因变量的患者中，对基线变量[TSS、HAQ、DAS 28、年龄、抗环瓜氨酸肽（抗CCP）状态、性别、MRI糜烂评分、MRI滑膜炎评分、MRI骨髓水肿评分]进行多变量线性回归分析。由于两个治疗组的结局相似，因此汇总了数据。结果：160例患者中共有120例完成了11年的随访。他们63（55-72）岁，68%在DAS 28缓解期（
Objective: To investigate the clinical and radiographic status, and to identify baseline predictors of functional status and erosive progression at 11 years' follow-up of early rheumatoid arthritis (RA) patients. Methods: Patients enrolled in the Danish investigator-initiated randomized controlled CIMESTRA trial, which investigated a 2 year treat-to-target intervention with methotrexate and intra-articular glucocorticoids with or without cyclosporine, were followed up. The 28-joint Disease Activity Score (DAS28), Health Assessment Questionnaire (HAQ) score, and total Sharp van der Heijde score (TSS) were assessed at baseline and 11 years. Baseline magnetic resonance imaging (MRI) of unilateral wrists was scored (OMERACT RAMRIS). Multivariable linear regression analyses of baseline variables [TSS, HAQ, DAS28, age, anti-cyclic citrullinated peptide (anti-CCP) status, gender, MRI erosion score, MRI synovitis score, MRI bone marrow oedema score] were performed in 96 patients with HAQ(11yrs) and increment TSS0-11yrs as dependent variables. Since outcomes were similar in the two treatment arms, data were pooled. Results: In total, 120 of 160 patients completed 11 years' follow-up. They were 63 (55-72) years old, 68% were in DAS28 remission (